190792-75-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester, (3S-cis)-(9CI) is used as a chiral building block for the synthesis of various pharmaceutical drugs. Its unique structure and properties make it a valuable component in the development of new medications.
Used in Organic Synthesis:
1-Pyrrolidinecarboxylicacid,3-amino-4-hydroxy-,1,1-dimethylethylester,(3S-cis)-(9CI) is also used in organic synthesis, where it serves as a reagent in chemical reactions. Its versatility and reactivity contribute to the synthesis of a wide range of organic compounds.
Used in Research and Development:
1-Pyrrolidinecarboxylic acid, 3-amino-4-hydroxy-, 1,1-dimethylethyl ester, (3S-cis)-(9CI) has been studied for its potential use in the treatment of certain medical conditions, such as cardiovascular disease and cancer. Its unique properties and potential therapeutic effects make it a promising candidate for further research and development in the medical field.

Upstream product

• 190792-84-8 (3S,4S)-3-azido-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 926913-20-4 (3R,4S)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 926912-91-6 (3R,4R)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 1214272-54-4 (3R,4S)-cis-N-Boc-3-hydroxy-4-azidopyrrolidine 
• 203434-45-1 (±)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 926912-99-4 (3S,4R)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 1214272-52-2 (3R,4R)-tert-butyl 3-azido-4-hydroxypyrrolidine-1-carboxylate 
• 926913-11-3 (3S,4S)-1-N-tert-butyloxycarbonyl-4-(4,4'-dimethoxytrityloxy)-3-mesyloxy-pyrrolidine 
• 1374429-77-2 (3R,4S)-tert-butyl 3-azido-4-(bis(4-methoxyphenyl)(phenyl)methoxy)pyrrolidine-1-carboxylate 
• 151259-38-0 tert-butyl diallylcarbamate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 1202067-37-5 (3R,4R)-3-hydroxy-4-(2,2,2-trifluoroacetylamino)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1202067-36-4 (3R,4R)-3-azido-4-(trimethylsilanyloxy)pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1202067-41-1 (3aS,6aR)-2-phenyl-3a,4,6,6a-tetrahydropyrrolo[3,4-d]oxazole-5-carboxylic acid tert-butyl ester 
• 1214272-56-6 (3S,4S)-trans-N-Boc-3-acetylthio-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1214272-57-7 (3S,4S)-trans-N-Boc-3-mercapto-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1214272-55-5 (3R,4S)-cis-N-Boc-3-hydroxy-4-(4-phenoxybenzenesulfonamido)pyrrolidine 
• 1215210-04-0 (3S,4S)-3-amino-4-hydroxypyrrolidine dihydrochloride 
• 1174020-29-1 cis-3-amino-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1215485-03-2 3,4-diaminopyrrolidinyl-1-carboxylic acid tert-butyl ester 
• 859213-33-5 (3S,4S)-tert-butyl 3-(dimethyl amino)-4-hydroxypyrrolidine-1-carboxylate 
• 138026-93-4 (trans)-tert-butyl hexahydropyrrolo[3,4-b][1,4]oxazine-6(2H)-carboxylate 

Relevant academic research and scientific papers

Guanidine derivative and application thereof

The invention relates to a guanidine derivative serving as a VAP-1 inhibitor and application of the guanidine derivative, and further relates to a pharmaceutical composition containing the compound. The compound or the pharmaceutical composition can be us

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS

The present invention relates to novel compounds of the general formula (I) their tautomeric forms, their enantiomers, their diastereoisomers, their pharmaceutically accepted salts, or pro-drugs thereof, which are useful for the treatment or prevention of cancer and inflammatory diseases associated with Interleukin-1 Receptor Associated Kinase (IRAK), and more particularly compounds that modulate the function of IRAK4.

Tetrahydroisoquinoline compound and its preparation method, pharmaceutical composition and use

The invention relates to a tetrahydroisoquinoline compound and its preparation method, pharmaceutical composition and use. The tetrahydroisoquinoline compound is shown by the general formula (1). In the general formula (1), the symbols have the same definitions as in the specification.

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').

INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE

The present disclosure is directed to compounds of formula I and methods of their use and preparation, as well as compositions comprising compounds of formula I.

Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core

New series of pyrrolidine mercaptosulfide, 2-mercaptocyclopentane arylsulfonamide, and 3-mercapto-4-arylsulfonamidopyrrolidine matrix metalloproteinase inhibitors (MMPIs) were designed, synthesized, and evaluated. Exhibiting unique properties over other MMPIs (e.g., hydroxamates), these newly reported compounds are capable of modulating activities of several MMPs in the low nanomolar range, including MMP-2 (～2 to 50 nM), MMP-13 (～2 to 50 nM), and MMP-14 (～4 to 60 nM). Additionally these compounds are selective to intermediate- and deep-pocket MMPs but not shallow-pocketed MMPs (e.g., MMP-1, ～850 to >50 000 nM; MMP-7, ～4000 to >25 000 nM). Our previous work with the mercaptosulfide functionality attached to both cyclopentane and pyrrolidine frameworks demonstrated that the cis-(3S,4R)-stereochemistry was optimal for all of the MMPs tested. However, in our newest compounds an interesting shift of preference to the trans form of the mercaptosulfonamides was observed with increased oxidative stability and biological compatibility. We also report several kinetic and biological characteristics showing that these compounds may be used to probe the mechanistic activities of MMPs in disease.

N -phosphonocarbonylpyrrolidine derivatives of guanine: A new class of Bi-substrate inhibitors of human purine nucleoside phosphorylase

A complete series of pyrrolidine nucleotides, (3R)- and (3S)-3-(guanin-9-yl)pyrrolidin-1-N-ylcarbonylphosphonic acids and (3S,4R)-, (3R,4S)-, (3S,4S)-, and (3R,4R)-4-(guanin-9-yl)-3-hydroxypyrrolidin-1-N- ylcarbonylphosphonic acids, were synthesized and e

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.